Additional Immunotherapies on the Horizon for LS-SCLC

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Anne Chiang, MD, PhD

Key Takeaways

Atezolizumab is being tested in the NRG-LU005 trial for limited-stage SCLC, assessing its efficacy alongside chemoradiation.
The NRG-LU005 trial is a randomized, phase III study comparing chemoradiation with or without atezolizumab.
The ADRIATIC trial differs by focusing on extensive-stage SCLC, highlighting distinct trial objectives.
Using a single immunotherapy across all SCLC stages may streamline treatment protocols, offering potential synergies and efficiencies.

Panelists discuss how atezolizumab is being investigated in the NRG-LU005 trial for limited-stage small cell lung cancer (SCLC), comparing its trial design with that of the ADRIATIC study, while also exploring the potential benefits of using a single immunotherapy across all SCLC stages and considering treatment strategies for patients who progress from limited-stage to extensive-stage disease while on immunotherapy.

EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC

EP: 2.Established Multidisciplinary Therapies for SCLC

EP: 3.Immunotherapies for Extensive-Stage SCLC

EP: 4.Introducing Bispecifics for Extensive-Stage SCLC

EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC

Now Viewing

EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC

EP: 7.Payer and Patient Education Considerations for SCLC

EP: 8.Biomarker Discovery and Exploration for SCLC

EP: 9.Key Takeaways on Recent Advances in SCLC

EP: 10.Therapies Beyond the Front Line for SCLC

EP: 11.Timing and Urgency Considerations in SCLC

Atezolizumab is also being investigated in the NRG-LU005 trial in patients with limited-stage small cell lung cancer (SCLC).

What potential role could atezolizumab have in patients with limited-stage disease?
What is the design of this trial?
How does the trial design differ from the ADRIATIC trial?

Are there synergies or efficiencies in using a single immunotherapy in all stages of SCLC?

If a patient progresses from limited-stage to extensive-stage disease on immunotherapy, do you switch therapies or continue the same regimen?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!